Evaluation of predictors and clinical outcome after tapering of chronic systemic corticosteroids in Behçet’s disease patients
- 5 November 2025
- journal article
- research article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (1) , 383-393
Abstract
Objectives To identify predictive factors for successful oral glucocorticoid (GC) tapering in a longitudinal cohort of Behçet’s disease (BD) patients in remission or with low disease activity, and to evaluate post-tapering outcomes over a one-year period. Methods This is an observational longitudinal cohort study, focusing on BD patients who began GC tapering and achieved remission or low disease activity. Patients who achieved sustained remission or low disease activity while maintaining a prednisone dose of ≤ 5 mg/day were classified as "successful tapering," while those who failed to achieve this outcome were classified as "failed tapering". A regression model was used to identify predictors of successful GC tapering to ≤ 5 mg/day. Results A total of 72 BD patients were enrolled and followed-up for 12 months. Multivariate analysis confirmed that short disease duration (odds ratio (OR) = 0.395, 95% CI: 0.197–0.794, p = 0.009), low activity at disease onset (OR = 0.177, 95% CI: 0. 037–0.846, p = 0.03), low severity score for BD at baseline (OR = 0.092, 95% CI:.010–0.876, p = 0.038), and low C-reactive protein value at baseline (OR = 0.186, 95% CI:0.039–0.883, p = 0.034) were the predictors for successful GC tapering. Conclusion The independent factors linked to success in tapering glucocorticoid in BD were shorter disease duration, low activity at disease onset, low severity score at baseline, and low C-reactive protein value. These findings suggest that they could be used in clinical settings to identify tapering candidates. Key Points •1- Behcet disease is a challenge to treat and usually necessitates a multidisciplinary strategy •2- Glucocorticoids have been used to treat almost all disease lesions •3- Long-term Glucocorticoids use is associated with adverse events •4- The independent factors linked to success in tapering glucocorticoid in Behcet disease were short disease duration, low activity at disease onset, low severity score at baseline, and low C-reactive protein value.Keywords
This publication has 44 references indexed in Scilit:
- Optimizing glucocorticoid therapy for Behçet's uveitis: efficacy, adverse effects, and advances in combination approachesInternational Ophthalmology, 2023
- Behçet SyndromeRheumatic Disease Clinics of North America, 2023
- Development of an Arabic version of the Behçet’s Disease Current Activity Form (Ar-BDCAF): cross-cultural adaptation and validation initiative in EgyptClinical Rheumatology, 2021
- Advances in the Treatment of Behcet’s DiseaseCurrent Rheumatology Reports, 2021
- Saudi cultural adaptation of the “compliance questionnaire of Rheumatology” for Rheumatoid arthritis patients on disease modifying anti-rheumatic drugs (DMARDs)Saudi Pharmaceutical Journal, 2021
- Clinical manifestations of Behçet’s disease in a large cohort of Chinese patients: gender- and age-related differencesClinical Rheumatology, 2020
- Long-term Systemic Corticosteroid Exposure: A Systematic Literature ReviewClinical Therapeutics, 2017
- Long-Term Outcomes and Predictors of Sustained Response in Patients with Intestinal Behcet’s Disease Treated with InfliximabDigestive Diseases and Sciences, 2017
- Outcome of a glucocorticoid discontinuation regimen in patients with inactive systemic sclerosisClinical Rheumatology, 2016
- Brief Report: Predicting Functional Disability: One‐Year Results From the Scottish Early Rheumatoid Arthritis Inception CohortArthritis & Rheumatology, 2016